Bridgefront Capital’s GSK GSK Stock Holding History

Bridgefront Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,531	Closed	-$411K	–	627
2025 Q3	$411K	Buy	9,531 +319	+3%	+$12.5K	0.12%	302
2025 Q2	$354K	Sell	9,212 -2,646	-22%	-$101K	0.09%	376
2025 Q1	$459K	Sell	11,858 -4,807	-29%	-$176K	0.13%	277
2024 Q4	$564K	Buy	16,665 +7,037	+73%	+$253K	0.19%	169
2024 Q3	$394K	Buy	+9,628	New	+$394K	0.15%	251
2024 Q1	–	Sell	-6,234	Closed	-$231K	–	450
2023 Q4	$231K	Buy	+6,234	New	+$224K	0.17%	248
2023 Q1	–	Sell	-13,785	Closed	-$484K	–	487
2022 Q4	$484K	Buy	+13,785	New	+$459K	0.34%	106
2021 Q3	–	Sell	-9,928	Closed	-$494K	–	479
2021 Q2	$494K	Buy	+9,928	New	+$477K	0.19%	176

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bridgefront Capital's GSK Position: Q4 2025 in Review

Bridgefront Capital sold out of GSK (GSK) in Q4 2025, closing a stake of 9,531 shares — an estimated $411K sold.

Bridgefront Capital first reported a position in GSK in Q2 2021 and held it in 8 quarters. The position peaked at $564K in Q4 2024. 995 funds tracked by Wall St. Rank hold GSK as of Q4 2025.

Bridgefront Capital reported no remaining GSK position as of Q4 2025 after selling out during the quarter.
Bridgefront Capital sold 9,531 GSK shares in Q4 2025, an estimated $411K.
Bridgefront Capital first reported a position in GSK in Q2 2021 and held it in 8 quarters.
Bridgefront Capital's GSK position peaked at $564K in Q4 2024.
995 funds tracked by Wall St. Rank held GSK as of Q4 2025.

Based on Bridgefront Capital's 13F filing for Q4 2025, filed 13 Feb 2026.